Approximately 163 employees will be impacted by the pending closure of Merck’s Cherokee plant with layoffs set to begin in ...
Phenom today unveiled the winners of its 2025 Talent Experience awards. The awards celebrate the extraordinary achievements ...
In a report released today, Matthew Weston from UBS maintained a Buy rating on Merck KGaA (0O14 – Research Report), with a price target of ...
ShareIn commemoration of the 2025 International Women’s Day, Merck Foundation, the philanthropic arm of Merck KGaA Germany and African First Ladies have reaffirmed their commitment to empowering women ...
In a report released today, James Quigley from Goldman Sachs maintained a Buy rating on Merck KGaA (0O14 – Research Report), with a price ...
The Federal Circuit reinstated a challenge of a Merck KGaA unit’s pigment patent by South Korea-based CQV Co. on Monday, ...
Clinical Trials Arena on MSN8d
Merck KGaA’s lupus drug fails in SLE cohort of Phase II trialMerck KGaA’s oral TLR7/8 inhibitor enpatoran has failed to meet the primary endpoint in a subgroup of patients, but ...
Pharmaceutical Technology on MSN9d
Merck KGaA reports YE24 earnings growth amid SpringWorks acquisition talksWhile the company is in discussions to acquire SpringWorks, it did not elaborate on these talks in its earnings call.
Q4 2024 Results Conference Call March 6, 2025 8:00 AM ETCompany ParticipantsFlorian Schraeder - Head of Investor ...
One of Merck KGaA’s leading immunology assets has flunked a phase 2 lupus trial. | One of Merck KGaA’s leading immunology ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback